SCN10A and myeloid sarcoma: It was subsequently shown that an administration of an orally bioavailable Nav1.8 antagonist (PF-01247324) improved cerebellar-dependent motor coordination in a transgenic mouse model overexpressing Scn10a as well as the EAE mouse model of MS [57, 58].